An Open-label Study of AZD0120 in Adults With Multiple Sclerosis

This study is testing a new drug called AZD0120 for adults with multiple sclerosis (MS). It is being evaluated both in people with relapsing forms of MS (whose disease has flare-ups) and progressive forms of MS (where disability steadily worsens). The drug aims to protect the nervous system and reduce disease activity. **You may be eligible if...** - You are between 18 and 75 years old - You have been diagnosed with relapsing MS (including active secondary progressive MS) according to 2017 diagnostic criteria — with evidence of recent disease activity and either poor tolerance of or inadequate response to a high-efficacy MS treatment - OR you have been diagnosed with primary progressive MS or non-active secondary progressive MS, with disability between EDSS 3.0 and 6.5, and have not responded well to at least one high-efficacy therapy - Your overall health is adequate based on screening tests **You may NOT be eligible if...** - You have not tried any high-efficacy disease-modifying therapy previously (in most cases) - You have significant liver, kidney, or immune problems - You have an active infection or significant uncontrolled medical condition - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.